Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Summary

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).

Timeline

Start

2021-11-23

Primary completion

2027-10-13

Completion

2027-10-13

Publications

• Steg PG, Goodman SG, Jukema JW, Martens P, Zirlik A, Bhatt DL, Menon V, Szarek M, Lesogor A, Stratz C, O'Donoghue F, Mena-Madrazo J, Shao Q, Liu K, Mehran R; VICTORION-2 Prevent Investigators. Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease. Am Heart J. 2026 May 26;300:107493. doi: 10.1016/j.ahj.2026.107493. Online ahead of print.

Drugs

Indications